IBT21

IBT21 (0.5-5 μM; overnight) inhibits UPR activation in HEK293A cells with an IC₅₀ of 0.61 μM^[1].
IBT21 is a more potent inhibitor of Tm-induced UPR activation in HEK293A and Hap1 cells, with an IC₅₀ of 0.95 μM^[1].
IBT21 inhibits the three branches of the UPR in HEK293A cells in a dose-dependent manner, with IC₅₀ values of 0.24 μM for ATF6, 0.33 μM for IRE1, and 0.46 μM for PERK^[1].
IBT21 (10 μM; overnight) inhibits the induction of downstream target genes of all three branches of the UPR in HEK293A cells, supporting its role as a chemical chaperone^[1].
IBT21 (10 μM; overnight) reduces the levels of Tm-induced SDS-resistant HMW BiP-containing complexes in HEK293A cells and prevents the aggregation of 125 proteins induced by Tm, including ER client proteins and protein homeostasis-related proteins^[1].
IBT21 (10 μM; overnight) directly inhibits intracellular protein aggregation and acts as a chemical chaperone in in vitro assays using human insulin at a concentration 100-fold lower than that of 4PBA^[1].
IBT21 (1-10 μM; 3 h) directly binds a large number of unfolded or misfolded proteins in HEK293A cells under ER stress, and significantly overlaps with the proteins whose aggregation it prevents, supporting its direct chemical chaperone mechanism^[1].
IBT21 (1-10 μM; 48 h) protects HEK293A cells against ER stress-induced cell death by restoring cell proliferation and viability in a dose-dependent manner^[1].
IBT21 (5 μM; 0-72 h) protects HEK293T cells against cytotoxicity induced by mutant prion protein overexpression and restores cell growth and viability^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.